British Journal of Medical & Surgical Urology
Volume 3, Issue 5 , Pages 204-209 , September 2010

Three-year outcomes of a visible haematuria clinic—No initial role for urine cytology?

  • Nicholas. P. Munro

      Affiliations

    • Royal Cornwall Hospital, Truro TR1 3LJ, UK
    • Corresponding Author InformationCorresponding author at: 7 The Parade, Truro, Cornwall, TR1 1QE, UK. Tel.: +44 1872 815260.
    • ,
  • Michael J. Stower

      Affiliations

    • York District Hospital, York YO31 8HE, UK
    • ,
  • Graeme H. Urwin

      Affiliations

    • York District Hospital, York YO31 8HE, UK
    • ,
  • Koon. H. Chan

      Affiliations

    • York District Hospital, York YO31 8HE, UK
    • ,
  • J. Russell Wilson

      Affiliations

    • York District Hospital, York YO31 8HE, UK

Received 19 September 2009 ,Revised 27 February 2010 ,Accepted 10 April 2010.

References 

  1. Kelly JD, Fawcett DP, Goldberg LC. Assessment and management of non-visible haematuria in primary care. BMJ. 2009;338:3021
  2. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163(2):524–527
  3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54(2):303–314
  4. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314–2330
  5. Chahal R, Gogoi NK, Sundaram SK. Is it necessary to perform urine cytology in screening patients with haematuria?. Eur Urol. 2001;39(3):283–286
  6. Viswanath S, Zelhof B, Ho E, Sethia K, Mills R. Is routine urine cytology useful in the haematuria clinic?. Ann R Coll Surg Engl. 2008;90(2):153–155
  7. Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, et al Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess. 2006;10(18):iii-iv, xi-259
  8. Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int. 2006;97(2):301–305
  9. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178(1):62–67
  10. Referral guidelines for suspected cancer. 2001;Crown copyright, http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4008746.
  11. Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, et al Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 2006;97(5):997–1001
  12. Konety BR, Metro MJ, Melham MF, Salup RR. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract. Urol Int. 1999;62(1):26–30
  13. Karl A, Tritschler S, Stanislaus P, Gratzke C, Tilki D, Strittmatter F, et al Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?. BJU Int. 2009;103(4):484–487
  14. Potter JM, Quigley M, Pengelly AW, Fawcett DP, Malone PR. The role of urine cytology in the assessment of lower urinary tract symptoms. BJU Int. 1999;84(1):30–31
  15. Hofland CA, Mariani AJ. Is cytology required for a hematuria evaluation?. J Urol. 2004;171(1):324–326
  16. Van Tilborg AA, Bangma CH, Zwarthoff EC. Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol. 2009;16(1):23–30
  17. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293(7):810–816
  18. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295(3):299–305
  19. Lotan Y, Shariat SF. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int. 2008;101(11):1362–1367
  20. Raina R, Pahlajani G, Ponsky LE, Agarwal A, Zippe CD. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. BJU Int. 2008;102(3):297–300
  21. Araki M, Nieder AM, Manoharan M, Yang Y, Soloway MS. Lack of progress in early diagnosis of bladder cancer. Urology. 2007;69(2):270–274

PII: S1875-9742(10)00093-5

doi: 10.1016/j.bjmsu.2010.04.002

British Journal of Medical & Surgical Urology
Volume 3, Issue 5 , Pages 204-209 , September 2010

Article Tools

* Image Usage & Resolution